Medivir Interim Report 1 Jan. -- 30 June 2004

Huddinge, SWEDEN


HUDDINGE, Sweden, July 06, 2004 (PRIMEZONE) -- Medivir's new share issue was fully subscribed in June, whereby the company raised SEK 322.5 m before deducting issue costs.

. A CD (candidate drug) was selected in the Cathepsin S protease inhibitor program against autoimmune deficiencies at the end of March.

. An EU patent was granted in late March on Medivir's herpes project ME-609.

. Medivir's preclinical research is maintaining positive progress. Major advances were made in the spring, on projects including the HCV and Cathepsin K (osteoporosis) programs.

. Net sales amounted to SEK 12.5 m in the period (138.6 inc. CCS, 53.4 exc. CCS).

. The loss after tax was SEK -92.5 m (-33.3 inc. CCS, -49.3 exc. CCS); earnings per share were SEK -8.61 (-3.88).

FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)8 546 83100 or +46 (0)70 853 7292.

FORTHCOMING FINANCIAL INFORMATION

The Nine-month Interim Report will be published on 26 October 2004 The Financial Statement will be published on 18 February 2005 The Three-month Interim Report will be published on 21 April 2005 The Annual General Meeting will be held on 21 April 2005, from 3 p.m.

Medivir's financial reports are available from its Website, www.medivir.se from these dates, under the 'Financial Information' heading.

The Medivir Group Medivir is an innovative, specialist research corporation that develops drugs with the objective of becoming a sustaining and profitable pharmaceuticals corporation. Medivir is located in Huddinge, Sweden and Cambridge, UK.

Medivir's research is oriented on developing new drug compounds based on polymerases and proteases as target enzymes. The group consists of Medivir AB, its subsidiary Medivir UK Ltd. and Medivir Personal AB. As of 30 June 2004, the group had 118 employees. Medivir was listed on the Stockholm Exchange O-list in 1996.

Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis). Medivir has five projects in clinical development phases, each with a unique clinical profile. The company's broad-based preclinical research portfolio houses five defined projects and nearly ten activities in various preclinical phases.

Medivir AB (publ), Lunastigen 7, 141 44 Huddinge, Sweden, tel (switchboard): +46 (0)8 546 83100

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download:

http://www.waymaker.net/bitonline/2004/07/06/20040706BIT00130/wkr0001.pdf

The full report